Welcome to our dedicated page for Marchex SEC filings (Ticker: MCHX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Investors tracking how Marchex monetizes conversational analytics often type natural questions like “Where can I find Marchex’s quarterly earnings report 10-Q filing?” or “Are Marchex SEC filings explained simply anywhere?” You’ll find both answers here. Stock Titan opens each document seconds after it appears on EDGAR and pairs it with an AI-driven summary, so you can jump straight to voice-analytics revenue, customer churn, or paid-media attribution metrics without scanning hundreds of pages.
Use our platform to follow Marchex insider trading Form 4 transactions or set alerts for Marchex Form 4 insider transactions real-time. Our AI surfaces key numbers and red-flag language, giving you the Marchex earnings report filing analysis that matters. Need help understanding Marchex SEC documents with AI? One click delivers plain-English guidance on liquidity, SaaS ARR trends, and goodwill impairments, plus side-by-side views of prior 10-Ks. Annual reports are no longer a slog; you get each Marchex annual report 10-K simplified alongside fresh benchmarks.
Looking into management incentives? The dedicated section on Marchex executive stock transactions Form 4 and every Marchex proxy statement executive compensation table makes cross-check seamless. For sudden developments, our dashboard lists each Marchex 8-K material events explained in everyday language, from leadership changes to major customer losses. Because we host every form—10-Q, 10-K, 8-K, S-8, and more—with real-time updates, AI-powered summaries, and expert commentary, you can move from data to decision faster than a sales call converts. Complex voice-analytics business, simple disclosures.
Marchex, Inc. reported softer results for Q3 2025 as revenue fell to $11.5 million from $12.6 million a year ago, reflecting lower call volumes, customer consolidations, migration effects, and macro headwinds. The quarter posted a net loss of $1.0 million (loss per share $0.02), compared with a $0.8 million loss in Q3 2024. Year to date, revenue was $34.6 million with a net loss of $2.9 million.
Operating expenses eased in product development but rose in general and administrative costs, including higher stock-based compensation, which totaled $0.9 million in Q3. Cash and equivalents were $10.3 million at September 30, 2025, down from $12.8 million at year-end; operating cash flow used was $1.5 million for the nine months. A domain asset sale generated a $0.6 million gain. Customer concentration remained notable: one customer represented 11% of Q3 revenue and 21% of receivables, with an independent dealer network at 15% of receivables. The 2025 share repurchase program (up to 3,000,000 Class B shares) had no buybacks. Subsequent to quarter-end, Marchex signed an agreement in principle to acquire Archenia via a $10 million 6% convertible note at $1.80 per share, subject to a definitive agreement and approval by disinterested stockholders, with closing anticipated in the first half of 2026.
Marchex, Inc. announced an Agreement in Principle to acquire 100% of Archenia, Inc. The consideration is a $10 million convertible promissory note at 6%, payable in three equal tranches on the 12, 18, and 24‑month anniversaries of the closing date. Principal and interest may convert into Class B common stock at $1.80 per share.
The agreement also includes potential contingent equity: for each of the first and second 12‑month periods after closing, if Archenia meets revenue and Adjusted EBITDA thresholds to be set in the definitive agreement, Marchex would issue 2 million shares for each such period.
A special committee of independent directors approved entering the AIP due to related‑party sellers. Next steps include negotiating a definitive agreement, obtaining Archenia audited financials and a fairness opinion, and securing approval by a majority of disinterested stockholders. If approved and executed, closing is anticipated in the first half of 2026. Separately, Marchex furnished its Q3 2025 earnings release as Exhibit 99.1.
Marchex, Inc. scheduled its 2025 Annual Meeting for December 16, 2025 at 11:00 AM PT at 1200 5th Ave., Suite 1300, Seattle, WA. Stockholders will vote on two items: electing five directors for a one-year term and ratifying RSM US LLP as independent auditor for the fiscal year ending December 31, 2025. The Board recommends voting FOR both proposals.
The record date is October 21, 2025. On that date, 4,660,927 Class A shares (25 votes per share) and 39,245,334 Class B shares (1 vote per share) were outstanding and will vote together as a single class. Russell Horowitz beneficially owns all Class A shares and additional Class B shares, representing 75.7% voting power. Notable Class B holders include Edenbrook Capital with 14,561,905 shares.
RSM audit fees were $439,900 for 2024 and $328,790 for 2023. Stockholders can access materials and vote via the Internet, telephone, or by mail upon request for printed copies.
Marchex, Inc. updated executive compensation and approved new equity awards. The Compensation Committee set annual base salaries at $400,000 for Troy Hartless (President & Chief Revenue Officer), $375,000 for Francis Feeney (Chief Operating Officer & Chief Legal Officer), and $275,000 for Brian Nagle (Chief Financial Officer), effective on the October 16, 2025 grant date.
The committee granted stock options of 150,000 to each of Hartless and Feeney and 125,000 to Nagle under the 2021 Stock Incentive Plan. Options vest over four years: 25% on the first anniversary of the grant date, then quarterly in equal 6.25% increments over the next three years, with an exercise price equal to the closing price on the grant date. It also granted RSUs of 150,000 to Hartless and Feeney and 125,000 to Nagle, each vesting in full on the fourth anniversary.
For Nagle, the company aligned employment terms with other executives. Upon certain terminations following a change in control, he is eligible for a lump sum equal to 12 months of base salary, prior-year earned bonus (capped at 100% of salary), and 12 months of COBRA. Death or disability provides 18 months of COBRA, and specified events trigger full vesting of unvested equity.
Marchex (MCHX) reported insider equity awards for its Chief Financial Officer dated 10/16/2025. The filing shows 125,000 restricted stock units tied to Class B Common Stock, which vest in full on the fourth anniversary of the grant date. It also lists 125,000 stock options with a $1.81 exercise price, expiring on 10/16/2035. The options vest 25% on the first anniversary, then quarterly over the following three years in equal 6.25% increments.
Marchex (MCHX) reported an insider equity grant to its Chief Operating Officer & CLO. On 10/16/2025, the executive received 150,000 restricted stock units, each settling into one share of Class B Common Stock, vesting in full on the fourth anniversary of the grant date.
On the same date, the executive was also granted 150,000 stock options with a $1.81 exercise price, expiring on 10/16/2035. The options vest over four years: 25% on the first anniversary, then quarterly in equal 6.25% increments over the next three years.
Marchex (MCHX) filed a Form 4 reporting equity awards to its President & Chief Revenue Officer effective October 16, 2025. The filing discloses 150,000 restricted stock units, each convertible into one share of Class B Common Stock, vesting in full on the fourth anniversary of the grant date. It also reports stock options for 150,000 shares at an exercise price of $1.81 per share, expiring October 16, 2035, vesting 25% on the first anniversary and the remainder in equal quarterly installments over the next three years.
Francis J. Feeney, Chief Operating Officer of Marchex, Inc. (MCHX), filed a Form 3 disclosing his initial beneficial ownership. The filing reports 277,428 shares of Class B common stock held directly and a portfolio of equity awards that could convert to additional shares.
The derivative holdings include employee stock options to purchase 848,000 shares with exercise prices ranging from $1.45 to $5.05 and expiration dates between 2028 and 2034, plus 62,500 restricted stock units that vest in full on the first anniversary of their March 20, 2025 grant. All reported holdings are direct and subject to specified vesting schedules tied to continued employment.
FAQ
What is the current stock price of Marchex (MCHX)?
What is the market cap of Marchex (MCHX)?
